Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

Modified-Release Drug Delivery Systems: Classification

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...

Modified-Release Drug Delivery Systems: Stimuli-Activated

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...

Oral Drug Delivery Systems: Delayed-Release Systems

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Risk factors for postoperative infection after non-elective femur fracture fixation in pediatric patients.

Injury·2026

Same author

Improved outcomes after anterior vertebral tethering for AIS using ideal versus acceptable indications.

Spine deformity·2026

Same author

Immediate chest tube removal at the completion of anterior vertebral tethering is well-tolerated without an increased risk of pulmonary complication.

Spine deformity·2025

Same author

Outcomes in patients with tether rupture after anterior vertebral tethering for adolescent idiopathic scoliosis: the good, the bad, and the ugly.

Spine deformity·2025

Same author

Fabricating vascularized, anatomically accurate bone grafts using 3D bioprinted sectional bone modules, in-situ angiogenesis, BMP-2 controlled release, and bioassembly.

Biofabrication·2024

Same author

Anterior vertebral tethering for adolescent idiopathic scoliosis: our initial ten year clinical experience.

Spine deformity·2024

Search research articles

Related Experiment Video

Updated: May 8, 2026

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Published on: October 8, 2016

Polymeric nanoparticles for a drug delivery system.

Brian E Grottkau¹, Xiaoxiao Cai, Jing Wang

¹State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, No.14., 3rd Sec, Ren Min Nan Road, Chengdu 610041, P.R. China. yunfenglin@scu.edu.cn.

Current Drug Metabolism

|September 11, 2013

Summary

Polymeric nanoparticles enhance anti-cancer drug delivery, improving treatment effectiveness and diagnostic accuracy. This review explores their advantages and applications, focusing on PHA and PLGA nanoparticles.

More Related Videos

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

Evaluation of Polymeric Gene Delivery Nanoparticles by Nanoparticle Tracking Analysis and High-throughput Flow Cytometry

Evaluation of Polymeric Gene Delivery Nanoparticles by Nanoparticle Tracking Analysis and High-throughput Flow Cytometry

Published on: March 1, 2013

Related Experiment Videos

Last Updated: May 8, 2026

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Published on: October 8, 2016

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

Evaluation of Polymeric Gene Delivery Nanoparticles by Nanoparticle Tracking Analysis and High-throughput Flow Cytometry

Evaluation of Polymeric Gene Delivery Nanoparticles by Nanoparticle Tracking Analysis and High-throughput Flow Cytometry

Published on: March 1, 2013

Area of Science:

Pharmacy and Nanotechnology
Drug Delivery Systems

Background:

Nanotechnology advancements are revolutionizing pharmaceutical drug delivery.
Polymeric nanoparticles offer stability for anti-neoplastic (anti-cancer) drugs.
They address challenges in therapeutic efficacy and diagnostic sensitivity.

Purpose of the Study:

To review the advantages of polymeric nanoparticles in drug delivery.
To discuss their specific applications in pharmaceutical research.
To highlight recent advancements in PHA-based and PLGA nanoparticles.

Main Methods:

Literature review of nanotechnology in pharmacy.
Analysis of polymeric nanoparticle properties and applications.
Focus on polyhydroxyalkanoates (PHA) and poly(lactic-co-glycolic acid) (PLGA) nanoparticles.

Main Results:

Polymeric nanoparticles demonstrate significant stability and improved drug delivery capabilities.
They show potential in enhancing both therapeutic outcomes and diagnostic sensitivity.
PHA and PLGA nanoparticles represent key areas of current research.

Conclusions:

Polymeric nanoparticles are a promising platform for advanced drug delivery systems.
Continued research into materials like PHA and PLGA is crucial for pharmaceutical innovation.
These nanoparticles offer a viable solution for improving anti-cancer drug therapy.